Transcatheter Aortic Valve Replacement Procedures

Transcatheter Aortic Valve Replacement Procedures

Global Transcatheter Aortic Valve Replacement Procedures Market to Reach US$18.3 Billion by 2030

The global market for Transcatheter Aortic Valve Replacement Procedures estimated at US$7.3 Billion in the year 2023, is expected to reach US$18.3 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2023-2030. Transfemoral Procedure, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Subclavian Procedure segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 13.0% CAGR

The Transcatheter Aortic Valve Replacement Procedures market in the U.S. is estimated at US$2.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 11.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Transcatheter Aortic Valve Replacement Procedures Market - Key Trends & Drivers Summarized

What are Transcatheter Aortic Valve Replacement Procedures and Why are They Critical?

Transcatheter Aortic Valve Replacement (TAVR) Procedures are minimally invasive surgeries used to treat severe aortic stenosis, a condition where the aortic valve becomes narrowed, restricting blood flow from the heart. TAVR procedures involve the insertion of a replacement valve via a catheter, usually through the femoral artery, eliminating the need for open-heart surgery. These procedures are critical for patients who are at high risk for conventional surgical aortic valve replacement (SAVR) due to age or comorbid conditions. TAVR offers a less invasive alternative with shorter recovery times and reduced risk of complications, making it a vital option for improving patient outcomes in aortic stenosis treatment.

How Do TAVR Procedures Enhance Patient Outcomes?

TAVR Procedures enhance patient outcomes by providing a safer and less invasive treatment option for severe aortic stenosis. The minimally invasive nature of TAVR results in shorter hospital stays, faster recovery times, and reduced pain compared to traditional open-heart surgery. This approach also minimizes the risk of complications, such as infections and bleeding, which are more common in open-heart procedures. TAVR has shown to significantly improve the quality of life for patients by alleviating symptoms of aortic stenosis, such as shortness of breath, fatigue, and chest pain. Additionally, TAVR is associated with lower mortality rates and better long-term survival, particularly in high-risk patients who are not suitable candidates for SAVR.

Why is the Adoption of TAVR Procedures Increasing?

The adoption of TAVR Procedures is increasing due to several critical factors. The aging global population and the rising prevalence of aortic stenosis, particularly among the elderly, create a growing demand for effective treatment options. Advances in medical technology and imaging techniques have improved the safety and efficacy of TAVR procedures, making them more accessible to a broader patient population. Clinical trials and studies demonstrating the benefits of TAVR over traditional surgical approaches have also contributed to its growing acceptance among healthcare providers. Additionally, the development of next-generation TAVR devices and expanding indications for their use, including intermediate-risk and low-risk patients, are driving the adoption of these procedures. The focus on improving patient outcomes and quality of life further propels the demand for TAVR as a preferred treatment option for aortic stenosis.

What Factors are Driving the Growth of the TAVR Procedures Market?

The growth in the Transcatheter Aortic Valve Replacement Procedures market is driven by several factors. The increasing prevalence of aortic stenosis, particularly among the aging population, creates a significant demand for effective treatment options. Technological advancements in TAVR devices and procedural techniques enhance the safety and efficacy of these procedures, driving their adoption. Clinical evidence supporting the benefits of TAVR over traditional surgical approaches contributes to its growing acceptance among healthcare providers and patients. Expanding indications for TAVR, including its use in intermediate-risk and low-risk patients, further fuel market growth. The emphasis on minimally invasive procedures that offer faster recovery times and improved patient outcomes also drives the demand for TAVR. Additionally, ongoing research and development efforts to improve TAVR technology and outcomes, along with favorable reimbursement policies, significantly contribute to market expansion.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Boston Scientific Corporation
• Bracco SpA
• Edwards Lifesciences Corporation
• Jenavalve Technology, Inc.
• Medtronic PLC
• Meril Life Sciences Pvt., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.